Misplaced Pages

Amulirafusp alfa: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 09:13, 27 December 2024 editGraeme Bartlett (talk | contribs)Administrators249,958 edits more ids← Previous edit Latest revision as of 05:05, 29 December 2024 edit undoJosve05a (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers155,221 editsm added orphan tagTag: AWB 
Line 1: Line 1:
{{Orphan|date=December 2024}}

{{Infobox drug {{Infobox drug
| type = mab | type = mab
Line 60: Line 62:
{{Reflist}} {{Reflist}}


⚫ {{Pharma-stub}}
] ]


⚫ {{Pharma-stub}}

Latest revision as of 05:05, 29 December 2024

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)
Pharmaceutical compound
Amulirafusp alfa
Monoclonal antibody
TypeBi-specific T-cell engager
SourceHuman
TargetCD20, SIRPα
Identifiers
CAS Number
UNII

Amulirafusp alfa (IMM0306) is a cancer immunotherapy that targets CD20-positive B-cell malignancies. It is a fusion protein that combines a CD20 monoclonal antibody with the CD47 binding domain of SIRPα, allowing it to simultaneously engage both CD20 and CD47 on cancer cells. Amulirafusp alfa has a dual mechanism of action that enhances both macrophage-mediated phagocytosis and natural killer cell activation.

References

  1. Yang J, Song Y, Zhou K, Li Z, Zhang M, Jing H, Wang Z, Yu L, Meng W, Lu Q, Tian W, Shi Y (December 2024). "Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a phase 1/2 study". Journal of Hematology & Oncology. 17 (1): 123. doi:10.1186/s13045-024-01646-2. PMC 11657391. PMID 39696680.
  2. Yang J, Li Z, Zhang M, Zhou K, Li Y, Yang Y, Wang Z, Yu L, Zhang J, Huang H, Cheng Y (September 2024). "839P Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma". Annals of Oncology. 35: S610. doi:10.1016/j.annonc.2024.08.890.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: